Press coverage about Tetraphase Pharmaceuticals (NASDAQ:TTPH) has trended somewhat positive on Friday, Accern reports. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Tetraphase Pharmaceuticals earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.9465605965527 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Tetraphase Pharmaceuticals Inc. (TTPH) Expected to Post Quarterly Sales of $2.23 Million (americanbankingnews.com)
- Relative Strength Index (RSI 14) in Focus: Diebold Nixdorf, Incorporated (NYSE:DBD), Tetraphase Pharmaceuticals … (stocksnewspoint.com)
- Comparable Company Analysis: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), Protalix BioTherapeutics, Inc … (journalfinance.net)
- Holding Stocks: Ascena Retail Group, Inc., (NASDAQ: ASNA), Tetraphase Pharmaceuticals, Inc., (NASDAQ: TTPH) (globalexportlines.com)
- Momentum Stocks in Focus (RSI – A Momentum Oscillator) RSI Alert Tetraphase Pharmaceuticals, Inc. (NASDAQ … (thestreetpoint.com)
TTPH has been the subject of several recent research reports. Gabelli upgraded Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 29th. HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, February 6th. B. Riley began coverage on Tetraphase Pharmaceuticals in a research report on Monday, February 12th. They issued a “buy” rating and a $11.00 price objective on the stock. BMO Capital Markets lowered Tetraphase Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 price objective on the stock. in a research report on Wednesday, February 14th. Finally, SunTrust Banks reissued a “buy” rating and issued a $10.00 price objective on shares of Tetraphase Pharmaceuticals in a research report on Wednesday, February 14th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $7.22.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.04. The business had revenue of $1.89 million for the quarter, compared to analyst estimates of $1.88 million. Tetraphase Pharmaceuticals had a negative return on equity of 85.70% and a negative net margin of 1,061.06%. research analysts expect that Tetraphase Pharmaceuticals will post -1.56 EPS for the current fiscal year.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.